Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, <scp>Double‐Blind</scp> , <scp>Placebo‐Controlled</scp> , Multiple Ascending Dose Study-Reference-Cited by-同舟云学术

Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double‐Blind , Placebo‐Controlled , Multiple Ascending Dose Study

Published:2022-07-27 Issue:10 Volume:4 Page:903-911
ISSN:2578-5745
Container-title:ACR Open Rheumatology
language:en
Short-container-title:ACR Open Rheumatology

Author:

Abuqayyas Lubna¹^ORCID,Cheng Laurence E.²,Teixeira dos Santos Marcia¹,Sullivan Barbara A.²,Ruiz‐Santiago Norma¹,Wang Hui¹,Zhou Yanchen²,Chindalore Vishala³,Cohen Stanley⁴,Kivitz Alan J.⁵,Posch Maximilian G.⁶,Parnes Jane R.¹

Affiliation:

1. Amgen Inc. Thousand Oaks California

2. Amgen Inc. South San Francisco California

3. Pinnacle Research Group Anniston Alabama

4. Metroplex Clinical Research Center Dallas Texas

5. Altoona Center for Clinical Research Duncansville Pennsylvania

6. Charité Research Organisation GmbH Berlin Germany

Publisher

Wiley

Subject

Rheumatology

Link